News

Prem Soman, MD, director of the Cardiac Amyloidosis Center and nuclear cardiology, and associate chief of cardiology at the University of Pittsburgh Medical Center Heart and Vascular Institute presented the late-breaking results from the long-term survival benefits and disease stabilization with the drug acoramidis in patients with transthyretin amyloid cardiomyopathy at ACC 2026.

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial

Patient outcomes clearly show acoramidis reduces both all-cause mortality and cardiovascular hospitalizations, but the study also reinforced the importance of early diagnosis and prompt medical therapy.

Johnson & Johnson announced the launch of its new Varipulse Pro pulsed field ablation (PFA) system in Europe following CE mark approval. It is five times faster at ablation delivery at a cooler temperature than the previous version.

Johnson & Johnson launches faster PFA system in Europe

The new version of the PFA system is five times faster than the current catheter to improve workflow.

The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to conduct a pivotal clinical trial for TRiCares Topaz transcatheter tricuspid valve replacement (TTVR) system in the U.S. The TTVR system uses two stent frames, one for the valve and one to engage the annulus with a membrane shirt between them to enable flexing of the outer ring to better seal against regurgitation.expansing stents

FDA clears way for IDE pivotal trial of the Topaz tricuspid valve replacement system

The TRiCares Topaz uses a unique two-stent frame valve prosthesis for better sealing and flexibility.

FTC warns Tennessee of coming price hikes if it rushes to remove restrictions on hospital chain

The state legislature is mulling over the passage of two bills: one that would eliminate Ballad’s status as a protected monopoly, and another that would remove the Certificate of Need, a barrier that forces healthcare entities to submit expansion proposals to regulators for approval. The issue, the FTC says, is related to timing.

Interventional radiologist 1st in world to deliver newly approved cancer treatment

The completion of the first treatment represents a "significant milestone" for patients with liver cancer, the IR who led the procedure says.

Cybersecurity experts believe AI is changing their work at a ‘fundamental’ level

Is the edge with the cybercriminals looking for weak points in firewalls? Or the security professionals trying to stop the bad guys from finding any?

cannabis weed marijuana heart health doctor cardiologist

Healthcare agencies mellow on medical cannabis as CMS launches Medicare hemp pilot

The Centers for Medicare & Medicaid Services unveiled a new program for alternative payment model participants that would allow clinicians to use products containing CBD as part of patient care plans. In response, the Food and Drug Administration vowed not to further restrict the sale of oral hemp products.

Hologic closing $18B merger deal as CEO announces retirement

The Marlborough, Massachusetts-based breast imaging vendor expects its sale to TPG and Blackstone to officially close on April 7.

Radiologists and other physicians question medicine’s ‘workaholic culture’

“Do we need to change the culture of medicine? Yes. But also, let doctors be doctors, and you’ll see how many of them happily work 60 hours a week," one noted radiologist wrote.

Medicare to boost payment for certain diagnostic imaging agents

CMS is moving forward with a proposal to issue separate reimbursement for radiopharmaceuticals—a change long lobbied for by the imaging industry.

Radiology AI vendor Volpara Health inks $7M Department of Defense contract

The feds will deploy solutions for advanced mammography reporting, cancer risk assessment and patient tracking across the military health system.

Medicare to more than double reimbursement for CCTA, likely spurring greater demand

Beginning Jan. 1, CMS will up the rate for cardiac computed tomography angiography from $175 to $357.13, "encouraging broader use for better patient outcomes.”

Around the web

Cardiovascular Business

Long-term cardiac amyloidosis survival benefits seen in extension acoramidis trial